

Disease Management Platform for Complex Chronic Disease

Jessica M. Gibson, CEO



PRECISION MEDICINE TOOLS ARE NEEDED FOR CHRONIC DISEASE

Start of symptoms



Complex Chronic Disease:

~75% of US Healthcare Expense \$ 2.3 TRILLION Annual Spending

Old Way

Healthcare has focused on treating and managing symptoms

The exact same symptoms can have very different origins or causes and need different management.


Precision Medicine

Identify the mechanisms specific the disease with genetics in the context of environment and lifestyle.

Use evidence based medicine to align therapeutics and targeted management to mitigate, prevent or even reverse disease progression.

DISEASES OF THE PANCREAS





Founder-Dr. David Whitcomb MD, PhD and established network of Medical Advisors and Customers

Stephen Pandol, MD Cedar Sinai Walter Park, MD Stanford Vikesh Singh, MD Johns Hopkins Samer Alkaade, MD St. Louis Suresh Chari, MD Mayo Clinic Gregory Cotes, MD MUSC




Darwin Conwell, MD Ohio State
Chris Forsmark, MD Florida
Mel Wilcox, MD MDDU Alabama
Michael Rickels, MD Penn
Andres Gelrude, Gastro-Health
Melena Belin, MD Minnesota

EXPERT SYSTEMS IDENTIFY DISEASE DRIVERS & SOLUTIONS


Each patient has a unique environment, lifestyle and events that contribute to disease onset and severity



Multiple co-morbidities are common, adding complexity



ARIEL'S PLATFORM DELIVERS THE RIGHT DATA DIRECTLY TO THE DECISION MAKER




Data Collection

Data Analysis

Decision Support

ARIEL CLASSIFIES PREVIOUSLY UNIDENTIFIABLE DISEASE DRIVERS FOR NEW THERAPEUTIC ALIGNMENTS & DRUG DEVELOPMENT

Same Symptoms






Self-Reinforcing Models can be applied to other diseases

Therapeutics Unfolded Protein Response Hypertriglyceridemia Oxidative stress generation Diabetes susceptibility **Immune** dysregulation **Fibrosis** susceptibility **Trypsin Pathway** Duct dysfunction

APPLY MECHANISTIC MODELS TO INFORM NEW EXPERT SYSTEMS

Organ Mechanism	Pancreas	GI Tract	Liver	Lungs
Inflammation (Immune system: innate, autoimmune)	Acute Pancreatitis / RAP	Gastroenteritis / colitis/ IBD	Hepatitis, NASH	Bronchitis, (Cystic fibrosis)
Fibrosis (Immune system)	Chronic pancreatitis	Crohn's Ulcerative colitis (UC)	Liver cirrhosis	COPD IPF
Pain (nerves, brain) - Inflammatory - Neuropathic - Affective	50% severe pain, 25% moderate pain	"Functional" bowel syndrome, chronic pain	NA	Dyspnea
Organ Dysfunction (epithelial cells, etc)	Maldigestion, Diabetes mellitus (Type 3C)	Diarrhea, Bowel obstruction, # Surgeries.	Portal hypertension, synthetic dysfunction	Cough, pneumonia, hypoxemia
Cancer (linked to inflammation)	Pancreatic ductal adenocarcinoma	Colorectal cancer (with UC)	Hepatocellular carcinoma	Lung cancer

DEMAND IS GROWING RAPIDLY: RAISING SERIES A LATE 2019



MILESTONES

Seed: use of funds Series A: use of funds **National Pancreas** Sales & Marketing Sales Team **Foundation Partnership Expanded Testing Panels Expert System Pilot** Launch Lipid Panel & **MVP** Digital Health Expert System EMR Integration **Expand Customer Base** Pharmacogenomics **Platform Expand International Markets** Marketing Campaign Insurance Pilot PancreasDx® launch Install in 10 US NPF Centers **Expanded Testing Panels** Reimbursement First Clinical Cases Study with Regenerative Launch Internationally Launch Platform Pharma funded studies Medicine Institute Pharma relationships ER Software tool pilot NIH funded studies expanded New Pharma Partnership 2016 2015 2019 Convertible Note

Seed \$4.5 M: Q2 2019

Pre-Seed \$2.4 M: 2016-2019

\$500 K: 2015

Series A \$8-10 M: 2020

OUTSTANDING, MULTIDISCIPLINARY TEAM



JESSICA GIBSON, MBA PRESIDENT, CEO



MARK HAUPT, MD CHIEF MEDICAL OFFICER



MICHAEL HARRIES PHD **ACTING CTO**



TORY MOORE, CFA CFO



JESSICA LARUSCH, PHD LEAD GENETIC SCIENTIST



WENDY FEIGEL, MHS **DIRECTOR OF OPERATIONS**



DAN SPAGNOLO, PHD **COMPUTATIONAL SYSTEMS BIOLOGIST**



JONATHAN VELEZ, MSIS **SOFTWARE ARCHITECT**



CAMERON BREZE BIOMEDICAL TECHNOLOGIST



KATYA ORLOVA, MS, CGC, PHD **VARIANT SCIENTIST**



SOLOMON ADAMS, PHARMD, PHD CELESTE SHELTON CGC,PHD PHARMACOGENOMICS EXPERT



VARIANT SCIENTIST

BENEFITS IMPACT MULTIPLE STAKEHOLDERS

"For the first time I feel like there is hope."

PATIENT

"I have proof that this is not in my head, there is something really causing this."

PATIENT

"Ariel Precision Medicine's PancreasDx is a major improvement over standard commercial tests."

PHYSICIAN

"This is what has been needed to help me treat my patients"

PHYSICIAN


"Ariel is putting out new information that is changing the way I look at my patients."

PHYSICIAN





PATIENTS



PHYSICIANS



PHARMA





ARIEL


Jessica M. Gibson

gibson@arielmedicine.com

5750 Centre Ave, Pittsburgh, PA



EXAMPLE OF THE EXPERT SYSTEM FOR CFTR



Ariel Precision Medicine Technology + Services

Advanced Clinical Support



Patient Clinical Context and Health Status FASTQ File from Sequenced Pancreatic Panel

QC Analysis & Variant Calling

Variant
Annotation,
Classification,
Prioritization

Contextualization of complex variants & clinical presentation

Clinical
Interpretation
Classification
& Reporting

Final Report & Medical Director Sign- out EMR Data
Integration,
Digital
Distribution


Data Provided by Institution

Ariel Precision Medicine Expert Systems

- Reports assembled & evaluated by multidisciplinary team of geneticists, variant scientist, expert physicians & genetic counselors, providing most advanced insights into report
- Save significant personnel time & effort by leveraging Ariel Platform
- First to offer clinical insights focused on aggregate impact of each patient's environment & genetic burden
- Receiving institution benefits from domain knowledge & evidence curated by dedicated team of pancreatic disease experts
- Analysis, clinical interpretation & report generation provided by Ariel



Ariel's Validated Real-time ED Tool



REVENUE SCENARIOS

